GFACX | SLCCX | GFACX / SLCCX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 24 years | 27 years | - |
Gain YTD | 21.055 | 22.196 | 95% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 1000 | 25% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 290B | 11.9B | 2,437% |
Annual Yield % from dividends | 0.00 | 0.00 | - |
Returns for 1 year | 28.04 | 21.21 | 132% |
Returns for 3 years | -3.58 | -21.65 | 17% |
Returns for 5 years | 45.21 | 7.92 | 571% |
Returns for 10 years | 52.57 | 53.45 | 98% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
IBDY | 26.46 | 0.03 | +0.11% |
iShares iBonds Dec 2033 Term Corp ETF | |||
GERM | 19.16 | N/A | N/A |
Amplify Treatments Testing and Advancements ETF | |||
UAPR | 30.04 | -0.06 | -0.21% |
Innovator U.S. Equity Ultra BffrETF™-Apr | |||
DFAE | 26.19 | -0.08 | -0.30% |
Dimensional Emerging Core Equity Mkt ETF | |||
EASG | 32.39 | -0.37 | -1.14% |
Xtrackers MSCI EAFE ESG Leaders Eq ETF |